1. At a Glance
Artemis Medicare Services Ltd (AMSL) reported a Q1 FY26 net profit of ₹21.4 crore on revenue of ₹250 crore, with margins holding at 16% OPM. The hospital chain (541 beds in Gurgaon + satellite centers) flexed a 28% YoY PAT growth—proving that even in healthcare, sometimes curing patients cures investor anxiety too. A fresh P/E sits at ~39×, expensive but cheaper than Apollo’s 72×. Stock trades 4.08× book, promoters trimmed their stake to 66.5%, and expansion is sucking cash like an ICU ventilator.
2. Introduction
Welcome to Artemis Medicare, where healing patients is serious business, but healing balance sheets is an art. Q1 FY26 painted a rosy picture: revenue surged 14%, EBITDA up 19%, and PAT jumped 28%. Yet the stock trades like a premium hospital suite—expensive and slightly intimidating to retail investors.
With 541 beds at its flagship Gurgaon facility, Artemis isn’t just another small hospital—it’s a growing tertiary-care brand in a market dominated by Apollo, Fortis, and Max. The group is diversifying through Artemis Daffodil (women/child care), Artemis Lite (secondary care), and Artemis Cardiac Care. Expansion is ongoing: ₹54 crore already sunk into new projects this quarter.
Is the prognosis bullish? Or will rising capex, debt, and promoter stake trimming make this patient crash? Grab your stethoscope, because we’re dissecting this report like a med-school cadaver.
3. Business Model (WTF Do They Even Do?)
Artemis operates a hub-and-spoke hospital network. The Gurgaon flagship (541 beds) is the cash cow, offering high-value treatments—orthopaedics, oncology, neurology, cardiology. These drive premium pricing and international medical tourism (~24% revenue from overseas patients). Satellite models (Lite, Cardiac Care, Solace) extend reach with lower capex.
Revenue mix:
- In-patient (IPD) ~70% (major surgeries, complex care)
- Out-patient (OPD) ~20%
- Diagnostics/Other ~10%
Margins ride on case mix (more neurosurgery = more money) and occupancy rates (~65-70%). Expansion is aggressive: new beds, partnerships, and a closed Chennai cardiac center (negligible revenue impact). While this model scales well, it’s capital-intensive—hence debt hovering at ₹280 crore.
4. Financials Overview
Fresh P/E calculation: Q1 EPS ₹1.54, annualized to ₹6.16; CMP ₹249 → P/E ≈ 40.4×.
Q1 FY26 highlights:
- Revenue: ₹250 cr (+14% YoY)
- EBITDA: ₹41 cr (+19% YoY), OPM 16%
- PAT: ₹21.4 cr (+28% YoY), margin 8.5%
- Net Debt: ₹280 cr
- ROCE: 14.9% | ROE: 12.9%
Commentary: Growth is healthy; margins expand slightly, driven by operational efficiency. However, debt remains chunky, and cash flows
